Tatton Consulting supported Test Valley-based cell and gene therapy company Laverock in its successful application to Future Economy Investor Partnerships SME round 1, awarded £689,672 by Innovate UK for the project Evaluation of a Programmable Immune Cell Therapy for Solid Tumours.
About the funded R&D project
Three cell therapies are currently NHS approved, all for blood cancers, with more in clinical evaluation. Solid tumours, including ovarian and several paediatric cancers, remain outside that reach. This project evaluates a programmable immune cell therapy, funded alongside private investment through the Investor Partnerships route, which pairs Innovate UK grant with aligned investor capital.
Award details
- Grant awarded: £689,672
- Competition: Future Economy Investor Partnerships SME round 1
- Competition year: 2023/24
- Project: Evaluation of a Programmable Immune Cell Therapy for Solid Tumours
- Sector: Cell and gene therapy
- UKRI project record: Gateway to Research, project 10079571
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
